All News

A clinical hold has been placed on the phase 1b CYAD-101-002 trial, examining pembrolizumab after treatment with CYAD-101 and folinic acid, fluorouracil, and oxaliplatin preconditioning in metastatic colorectal cancer.

Patients treated with ceritinib who had ALK-positive non–small cell lung cancer with active brain metastases and/or leptomeningeal disease experienced encouraging responses in the phase 2 ASCEND-7 trial.

A significant progression-free survival benefit was observed with the use of capecitabine maintenance therapy in newly diagnosed nasopharyngeal carcinoma vs best supportive care.

At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.

Thomas Martin, MD, spoke about how to increase response durability with ciltacabtagene autoleucel for patients with heavily pretreated multiple myeloma.

Following a submission of updated survival data, the FDA has extended the Prescription Drug User Fee Act date for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Treatment with a hypomethylating agent plus venetoclax followed by hematopoietic stem cell transplant could improve outcomes in patients with treated secondary acute myeloid leukemia.

Topline findings from the phase 3 SIENDO trial did not appear to likely support a supplemental new drug application use of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer, prompting the creation of a new phase 3 trial to support a future submission.

Elderly patients with multiple myeloma who were treated with first-line bortezomib had a higher risk of falls vs age-matched controls.

Ruben Mesa, MD, spoke about which patients stand to benefit the most from the approval of pacritinib in myelofibrosis with severe thrombocytopenia.

Eleni Efstathiou, MD, PhD, spoke about how results of the phase 3 MAGNITUDE trial, which examined the combination of niraparib with abiraterone acetate and prednisone, have the ability to change the standard of care in patients with metastatic castration-resistant prostate cancer.

Patients with squamous cell carcinoma of the head and neck who had progressive disease following treatment with platinum-based chemotherapy and a checkpoint inhibitor experienced promising safety and preliminary efficacy following treatment with tisotumab vedotin.

New findings indicate that mechanisms of genomic escape seen in covalent and some noncovalent Burton tyrosine kinase inhibitors could be responsible for drug resistance in relapsed/refractory chronic lymphocytic leukemia.

Thomas Martin, MD, spoke about which patient population with relapsed/refractory multiple myeloma would benefit most from treatment with ciltacabtagene autoleucel.

The combination of tremelimumab plus durvalumab improved survival for patients with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial.

Phase 2 data highlighted a high complete response rate and undetectable minimal residual disease rate in patients with indolent clinical forms of mantle cell lymphoma who received ibrutinib plus rituximab.

A supplemental new drug application has been submitted to the FDA for ibrutinib to help treat pediatric and adolescent patients with chronic graft versus host disease.

Ofer Sharon, MD, spoke about the PROphet diagnostic platform for non–small cell lung cancer and the latest interim results from the prospective PROPHETIC trial in the most recent episode of CancerNetwork’s® "Oncology Peer Review On-The-Go" podcast.

The inaccuracy of standard immunohistochemistry testing to identify ERBB2-low breast cancer could lead to real-world mismanagement of patients who may be eligible for fam-trastuzumab deruxtecan-nxki.

Patients with intermediate- or high-risk primary or secondary myelofibrosis with a low platelet count may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.

Ruben Mesa, MD, spoke about the accelerated approval of pacritinib and its importance for the treatment of myelofibrosis with severe thrombocytopenia.

Patients with heavily pretreated relapsed/refractory multiple myeloma may now receive treatment with ciltacabtagene autoleucel following its approval by the FDA.

Thomas Martin, MD, spoke about the importance of the approval of ciltacabtagene autoleucel to treat patients with pretreated multiple myeloma.

Jun Gong, MD, hosted a Twitter takeover during the 2022 Genitourinary Cancers Symposium where he discussed breaking presentations in a #CNRealtimeReport.

Patients with early stage glottic larynx carcinoma benefitted from treatment with tumor-focused stereotactic radiotherapy.

Based on results from the CheckMate-816 trial, the FDA has accepted a supplemental biological license agreement for nivolumab plus chemotherapy for patients with resectable non–small cell lung cancer.

In recognition of Black History Month, key opinion leaders from the community oncology space and beyond speak to how organizations are working to diversify clinical cancer research and combat outcome disparities.

Chung-Han Lee, MD, PhD, spoke about interesting findings that arose from the KEYNOTE-146 study for patients with metastatic renal cell carcinoma.

Younger survivors of B-cell non-Hodgkin lymphoma appeared to have an increased risk of adverse health outcomes 5 or more years after diagnosis compared with older survivors.

Patients with advanced midgut neuroendocrine tumors experienced a clinically relevant improvement in median overall survival when treated with 177Lu-Dotatate compared with the control of high-dose long-acting octreotide, although the difference was not significant.